- Conditions
- HIV Infection
- Interventions
- Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 94
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- GSK1349572, Raltegravir, GSK1349572 Placebo, Raltegravir Placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 52 more
- Conditions
- HIV Infections
- Interventions
- Raltegravir, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- San Francisco, California
- Conditions
- HIV-1 Infection
- Interventions
- Vesatolimod, Placebo, ARV regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Diego, California • Ft. Pierce, Florida + 5 more
- Conditions
- HIV-1 Infection
- Interventions
- Vesatolimod, Placebo, ART
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Ft. Pierce, Florida + 3 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 25 more
- Conditions
- HIV Infections
- Interventions
- Dolutegravir 50 mg twice daily, Dolutegravir placebo twice daily
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 21 more
- Conditions
- HIV Infections
- Interventions
- Raltegravir (MK-0518), Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more
- Conditions
- Infection, Human Immunodeficiency Virus I
- Interventions
- GSK1349572 (dolutegravir), raltegravir, GSK1349572 Placebo, ABC/3TC, TDF/FTC, raltegravir Placebo
- Drug · Other
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 828 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more
- Conditions
- HIV-1 Infection
- Interventions
- F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more
- Conditions
- HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
- Interventions
- raltegravir, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV-1 Infection
- Interventions
- FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more